TY - JOUR
T1 - A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab
T2 - updated efficacy and biomarker analyses
AU - Cameron, David
AU - Casey, Michelle
AU - Press, Michael
AU - Lindquist, Deborah
AU - Pienkowski, Tadeusz
AU - Romieu, C Gilles
AU - Chan, Stephen
AU - Jagiello-Gruszfeld, Agnieszka
AU - Kaufman, Bella
AU - Crown, John
AU - Chan, Arlene
AU - Campone, Mario
AU - Viens, Patrice
AU - Davidson, Neville
AU - Gorbounova, Vera
AU - Raats, Johannes Isaac
AU - Skarlos, Dimosthenis
AU - Newstat, Beth
AU - Roychowdhury, Debasish
AU - Paoletti, Paolo
AU - Oliva, Cristina
AU - Rubin, Stephen
AU - Stein, Steven
AU - Geyer, Charles E
PY - 2008
Y1 - 2008
N2 - Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab. Updated efficacy and initial biomarker results from this trial are reported.
AB - Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab. Updated efficacy and initial biomarker results from this trial are reported.
U2 - 10.1007/s10549-007-9885-0
DO - 10.1007/s10549-007-9885-0
M3 - Article
C2 - 18188694
VL - 112
SP - 533
EP - 543
JO - Breast cancer research and treatment
JF - Breast cancer research and treatment
IS - 3
ER -